A recent study compared the effect of adding exenatide(Byetta) or insulin glargine (Lantus) to type 2 patients’treatment regimens. The type 2s previously had been takingmetformin and a sulfonylurea with little success.
According to the researchers, patients taking Byetta atdosages of 10 micrograms twice daily achieved reductions inglucose measures similar to those of patients taking Lantus.
“[Byetta] reduced postprandial glucose excursions morethan insulin glargine, while insulin glargine reduced fastingglucose concentrations more than [Byetta],” write theresearchers.
Byetta patients also lost an average of 5 pounds, whilepatients on Lantus gained an average of 4 pounds. Rates ofsymptomatic hypoglycemia were similar between treatmentgroups.
The most common adverse event for Byetta users wasnausea, which was experienced by 57 percent of theparticipants. Six percent of Byetta participants discontinuedits use due to nausea.
—Annals of Internal Medicine, October 18, 2005